EPIZYME, INC. (NASDAQ:EPZM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Epizyme, Inc. (the “Company”) previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2016 that Robert Copeland, President of Research and Chief Scientific Officer, would be retiring from the Company on a date to be determined in the second quarter of 2017 to pursue advisory and other opportunities within the industry. The Company and Dr. Copeland have determined that Dr. Copeland’s retirement will be effective June 30, 2017, and that Dr. Copeland will not provide ongoing advisory services to the Company.
About EPIZYME, INC. (NASDAQ:EPZM)
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.
